Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Her2 (show ERBB2 Antibodies), cMet and FGFR2 (show FGFR2 Antibodies) statuses were profiled in gastric cancer (GC) patients and the -derived tumor xenograft(PDX) models.
Cells with ectopic FOXM1 (show FOXM1 Antibodies) expression demonstrate considerable ( approximately 20%, P < 0.001) growth advantage despite MET targeting.
MET exon 14 skipping was detected in 1.3% (23/1770) of the Chinese patients with Non-Small Cell Lung Cancer (NSCLC). MET exon 14 skipping defined a new molecular subset of NSCLC with identifiable clinical characteristics. The therapeutic EGFR (show EGFR Antibodies) inhibitors might be an alternative treatment for patients with MET mutant NSCLC.
FKBP12 binding is required for full Met activation and everolimus can inhibit Met
c-Met may have a role in response to EGFR (show EGFR Antibodies)-TKI treatment in advanced non-small cell lung cancer
Study shows that Met and HGF (show HGF Antibodies) have a multi-factorial relationship to the biology and outcome of breast cancer, influenced by gene copy number and protein expression, activation status, stromal environment, and cellular localisation
this study of cabozantinib (a dual VEGFR2 (show KDR Antibodies)/MET) in metastatic TNBC, while not meeting its prespecified endpoint, showed that treatment is associated with circulating biomarker changes, and is active in a subset of patients.
The oleocanthal-based homovanillyl sinapate is a novel c-Met inhibitor which reduced tumor growth orthotopic model of triple negative breast cancer.
Studies indicate that miR (show MLXIP Antibodies)-182 negatively regulated Met via direct binding to the Met 3'-untranslated region (3'-UTR (show UTS2R Antibodies)).
Selective MET tyrosine kinase (show TXK Antibodies) inhibitor SAR125844 has significant antitumour activity in patients with MET-amplified non-small cell lung carcinoma.
possible cooperative role of the EGF (show EGF Antibodies) and HGF (show HGF Antibodies) pathways and indicate that cross-talk between their respective receptors may modulate mammary gland development in the cow
The proto-oncogene MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Various mutations in the MET gene are associated with papillary renal carcinoma. Two transcript variants encoding different isoforms have been found for this gene.
, HGF/SF receptor
, SF receptor
, hepatocyte growth factor receptor
, met proto-oncogene tyrosine kinase
, proto-oncogene c-Met
, scatter factor receptor
, tyrosine-protein kinase Met
, HGF receptor c-Met
, hepatocyte growth factor
, hepatoCyte growth factor receptor
, met proto-oncogene
, Hepatocyte growth factor receptor
, hepatocyte growth factor receptor-like
, Proto-oncogene c-Met
, Scatter factor receptor
, Tyrosine-protein kinase Met